Vimarsana
Biggest News Aggregation in the World

Page 4 - John Savin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from John Savin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In John Savin Today - Breaking & Trending Today

Numinus expanding revenue and territory with Novamind acquisition - Vimarsana News

Numinus expanding revenue and territory with Novamind acquisition

Numinus Wellness Inc has created a North American integrated business delivering mental health wellness services through clinics offering evidence-based...

Numinus Wellness Inc in detail - Vimarsana News

Numinus Wellness Inc in detail

John Savin, a research analyst at Proactive, joined Katie to talk about Numinus Wellness. Numinus runs five psychedelic wellness clinics in Canada and is on...

Related Topics:
John Savin
Tiziana Life Sciences: Method of therapy delivery gives firm 'a novel market position' - Vimarsana News

Tiziana Life Sciences: Method of therapy delivery gives firm 'a novel market position'

Proactive Research analyst John Savin presents his research Tiziana Life Sciences which uses its delivery technology to administer its fully human...

Open Orphan 'anticipating rapid rise in sales from £23m in FY20 to FY21 of £37m' says Proactive Research - Vimarsana News

Open Orphan 'anticipating rapid rise in sales from £23m in FY20 to FY21 of £37m' says Proactive Research

Proactive Research analyst John Savin presents his analysis on Open Orphan PLC (AIM:ORPH, OTC:OPORF)'s (Open Orphan PLC (AIM:ORPH,...

Edison Investment Research Limited: ReNeuron Group (RENE): Continuing to Gain Clinical Data in Eye Disease - Vimarsana News

Edison Investment Research Limited: ReNeuron Group (RENE): Continuing to Gain Clinical Data in Eye Disease

Edison Investment Research Limited: ReNeuron Group (RENE): Continuing to Gain Clinical Data in Eye Disease LONDON, UK / ACCESSWIRE / January 15, 2021 / After an eventful 2020, ReNeuron released updated 12-month Phase ll data in January on its lead human retinal progenitor cell (hRPC) project. This continues to show a consistent and robust, sustained average gain in visual acuity in retinitis pigmentosa (RP). A continuation study in nine patients using two million cells is underway with three- and six-month data due over H2 CY21 and the first three patients treated. This will facilitate partne...